Login to Your Account



Clinic Roundup


Thursday, May 3, 2012

• Versartis Inc., of Redwood City, Calif., said it completed patient enrollment in a Phase I trial of VRS-317, a once-monthly form of recombinant human growth hormone. The primary objective of the study is to evaluate the safety and tolerability of a single subcutaneous dose of the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription